FDA Approves Elan's Verelan PM
Elan and Schwarz Pharma have received marketing authorization from theUS Food and Drug Administration for Verelan PM (verapamil), a chronotherapeutic formulation of the established calcium antagonist for the treatment of essential hypertension.
Elan's proprietary CODAS (Chronotherapeutic Oral Drug Absorption System) is used in the product and allows bedtime dosing. It incorporates a four-to-five-hour delay in drug delivery, resulting in maximal levels of plasma verapamil in the morning.
Elan granted the exclusive marketing rights in the USA for Verelan PM and Verelan to Schwarz Pharma after acquisition of the franchise from Wyeth-Ayerst. Schwarz now plans to expand its sales force to ensure effective coverage of the market for the launch of Verelan PM.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze